UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Increases Holdings in Sabra Healthcare REIT, Inc. $SBRA

Key Points

• UBS Asset Management increased its holdings in Sabra Healthcare REIT by 16.8% during the first quarter, owning approximately 1.7 million shares valued at $29.5 million.
• Several institutional investors also boosted their positions in Sabra Healthcare REIT, with D. E. Shaw & Co. increasing holdings by 749.3% and Nuveen Asset Management lifting theirs by 30.8% in the fourth quarter.
• Analysts have raised their price targets for Sabra Healthcare REIT, with JMP Securities and BMO Capital Markets setting targets at $22.00, indicating a consensus rating of Moderate Buy among investment analysts.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Free Report) by 16.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,687,977 shares of the real estate investment trust's stock after purchasing an additional 243,274 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.71% of Sabra Healthcare REIT worth $29,489,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of SBRA. D. E. Shaw & Co. Inc. lifted its holdings in Sabra Healthcare REIT by 749.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 221,992 shares of the real estate investment trust's stock valued at $3,845,000 after acquiring an additional 195,854 shares during the period. Focus Partners Wealth lifted its holdings in Sabra Healthcare REIT by 4.0% in the fourth quarter. Focus Partners Wealth now owns 20,771 shares of the real estate investment trust's stock valued at $360,000 after acquiring an additional 797 shares during the period. Lazard Asset Management LLC lifted its holdings in Sabra Healthcare REIT by 44.2% in the fourth quarter. Lazard Asset Management LLC now owns 71,847 shares of the real estate investment trust's stock valued at $1,244,000 after acquiring an additional 22,019 shares during the period. Nuveen Asset Management LLC lifted its holdings in Sabra Healthcare REIT by 30.8% in the fourth quarter. Nuveen Asset Management LLC now owns 3,378,733 shares of the real estate investment trust's stock valued at $58,520,000 after acquiring an additional 795,902 shares during the period. Finally, Nomura Holdings Inc. acquired a new position in Sabra Healthcare REIT in the fourth quarter valued at approximately $988,000. 99.40% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on SBRA shares. JMP Securities boosted their price target on Sabra Healthcare REIT from $20.00 to $22.00 and gave the company a "market outperform" rating in a report on Wednesday, August 6th. BMO Capital Markets boosted their price target on Sabra Healthcare REIT from $19.00 to $22.00 and gave the company a "market perform" rating in a report on Monday, August 25th. Wells Fargo & Company boosted their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, August 27th. Truist Financial boosted their price objective on Sabra Healthcare REIT from $18.00 to $20.00 and gave the company a "hold" rating in a research report on Tuesday, September 2nd. Finally, Scotiabank boosted their price objective on Sabra Healthcare REIT from $19.00 to $20.00 and gave the company a "sector perform" rating in a research report on Monday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $20.83.

Sabra Healthcare REIT Price Performance

Shares of NASDAQ SBRA opened at $19.19 on Tuesday. The firm has a 50-day simple moving average of $18.70 and a 200-day simple moving average of $18.01. The company has a quick ratio of 4.80, a current ratio of 4.80 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $4.60 billion, a price-to-earnings ratio of 25.25, a price-to-earnings-growth ratio of 1.52 and a beta of 0.88. Sabra Healthcare REIT, Inc. has a 52 week low of $15.60 and a 52 week high of $20.03.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The real estate investment trust reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.02. The company had revenue of $189.15 million during the quarter, compared to analysts' expectations of $185.64 million. Sabra Healthcare REIT had a net margin of 24.87% and a return on equity of 6.69%. Sabra Healthcare REIT's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.36 EPS. Sabra Healthcare REIT has set its FY 2025 guidance at 1.450-1.470 EPS. On average, equities analysts predict that Sabra Healthcare REIT, Inc. will post 1.45 earnings per share for the current fiscal year.

Sabra Healthcare REIT Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Friday, August 15th were issued a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 6.3%. The ex-dividend date of this dividend was Friday, August 15th. Sabra Healthcare REIT's dividend payout ratio (DPR) is currently 157.89%.

Sabra Healthcare REIT Company Profile

Sabra Health Care REIT, Inc engages in the business of acquiring, financing, and owning real estate property. The company was founded on May 10, 2010 and is headquartered in Tustin, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.